DFDA

Daclatasvir + Sofosbuvir

Treatment for Acute Hepatitis C

Typical Dosage: Sofosbuvir 400 mg once daily + Daclatasvir 60 mg once daily

Effectiveness
95%
Safety Score
68%
Clinical Trials
30
Participants
6K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
68
DangerousModerateSafe
Treatment Details
Dosage Range
Sofosbuvir 400 mg once daily + Daclatasvir 60 mg once daily
Time to Effect
Within 12-24 weeks of treatment completion
Treatment Duration
12 weeks
Evidence Quality
HIGH
Number Needed to Treat (NNT)
1(Treat 1 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
100(Treat 100 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$12,000
Monitoring:$1,000
Side Effect Mgmt:$200
Total Annual:$13,200
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOOD
ICER
$75,000/QALY
QALYs Gained
2.5
Outcome-Based Costs
Cost per Responder
$13,895
Cost per Remission
$13,895
Comparison vs Pegylated Interferon + Ribavirin
Cost Difference
$-21,800/year
Less expensive
QALY Difference
+2.00 QALYs
Better outcomes
Dominance
DOMINATESBetter + cheaper
Daclatasvir + Sofosbuvir Outcomes

for Acute Hepatitis C

Efficacy Outcomes
Overall Effectiveness
+95%
Response Rate
+95%
Remission Rate
+95%
Common Side Effects
Headache
+18%
Fatigue
+12%
Nausea
+7%
Diarrhea
+4%

Sources:

nih.gov
oup.com
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov